Clinical trials
Completed Skin Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
272 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 9 |
| 2004 | 7 |
| 2005 | 10 |
| 2006 | 4 |
| 2007 | 15 |
| 2008 | 18 |
| 2009 | 13 |
| 2010 | 6 |
| 2011 | 12 |
| 2012 | 9 |
| 2013 | 10 |
| 2014 | 13 |
| 2015 | 13 |
| 2016 | 12 |
| 2017 | 19 |
| 2018 | 12 |
| 2019 | 11 |
| 2020 | 13 |
| 2021 | 10 |
| 2022 | 11 |
| 2023 | 7 |
| 2024 | 9 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 272 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 20 |
| Klein Buendel, Inc. | 9 |
| M.D. Anderson Cancer Center | 8 |
| H. Lee Moffitt Cancer Center and Research Institute | 7 |
| Northwestern University | 7 |
| Stanford University | 5 |
| Massachusetts General Hospital | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Pfizer | 4 |
| University of Arizona | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Skin Neoplasms | 272 |
| Melanoma | 94 |
| Basal Cell Carcinoma | 40 |
| Neoplasms | 34 |
| Carcinoma, Squamous Cell | 28 |
| Lung Neoplasms | 21 |
| Breast Neoplasms | 19 |
| Head and Neck Neoplasms | 19 |
| Prostatic Neoplasms | 12 |
| Urinary Bladder Neoplasms | 12 |
Trials
Showing 76 to 100 of 272. Each trial links to its page on Pharma Observatory.
172 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.